companies / siriustx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-17 json
| total_raised | 100,000,000100.0M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | San Diego, United States | |
| industry | unknown | |
| stage | series-b+ |
Sirius Therapeutics is a clinical-stage biotech developing long-acting siRNA therapies for cardiovascular disease, led by SRSD107, a Factor XI inhibitor for thromboembolic disorders. It targets patients at risk of thrombosis where anticoagulants raise bleeding risk. Its edge is selective Factor XI silencing with minimal impact on normal hemostasis.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-05-01 | series-b | 50,000,00050.0M | null | ○ |
hsts, nginx, openresty
| fact | status | src |
|---|---|---|
| Series B, $50.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |